Voyager Therapeutics (VYGR) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.9 million.
- Voyager Therapeutics' Income from Continuing Operations fell 20840.34% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 58988.41%. This contributed to the annual value of -$65.0 million for FY2024, which is 14912.11% down from last year.
- According to the latest figures from Q3 2025, Voyager Therapeutics' Income from Continuing Operations is -$27.9 million, which was down 20840.34% from -$33.4 million recorded in Q2 2025.
- Over the past 5 years, Voyager Therapeutics' Income from Continuing Operations peaked at $124.0 million during Q1 2023, and registered a low of -$34.5 million during Q4 2024.
- Moreover, its 5-year median value for Income from Continuing Operations was -$22.2 million (2023), whereas its average is -$7.7 million.
- In the last 5 years, Voyager Therapeutics' Income from Continuing Operations crashed by 56669.3% in 2022 and then soared by 68184.72% in 2023.
- Over the past 5 years, Voyager Therapeutics' Income from Continuing Operations (Quarter) stood at $5.1 million in 2021, then plummeted by 566.69% to -$23.6 million in 2022, then soared by 338.86% to $56.4 million in 2023, then crashed by 161.15% to -$34.5 million in 2024, then increased by 19.12% to -$27.9 million in 2025.
- Its Income from Continuing Operations was -$27.9 million in Q3 2025, compared to -$33.4 million in Q2 2025 and -$31.0 million in Q1 2025.